

Ref. No. JPL/CS/1511/2018

Date : 31st July, 2018.

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Sub.: Outcome of Board Meeting held today, i.e. 31st July, 2018 – Unaudited Results for the Quarter ended 30th June, 2018.

Reg.: Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Dear Sir,

Kindly note that the Audit Committee have reviewed and the Board of directors of the Company have approved the unaudited financial results for the quarter ended on 30th June, 2018 during their respective meetings held today, i.e. on 31st July, 2018.

The unaudited financial results for the quarter from 1st April, 2018 to 30th June, 2018 duly signed in the format specified under clause 30(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, is enclosed.

Also enclosed alongwith is the limited audit review report of the auditors of the Company, on the unaudited financial results for the quarter ended on 30th June, 2018.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Ltd.,



(ASHISH SHAH)
Company Secretary.

Encl.: As Stated Above.

Statement of Unaudited Standalone Financial Results for the Quarter Ended on 30/06/2018

Rs. In Lacs other than EPS

Sr. No.	Particulars	Quarter Ended			Year Ended
		30/06/2018	31/03/2018	30/06/2017	31/03/2018
		Unaudited	Audited	Unaudited	Audited
1	Revenue from Operations	2325.82	3005.82	1699.40	11467.42
2	Other Income	90.53	64.81	111.09	339.40
3	Total income	2416.35	3070.63	1810.49	11806.82
4	Expenses				
	(a) Cost of Materials Consumed	248.96	336.95	189.46	986.21
	(b) Purchase of Stock-in-trade	568.74	757.88	479.30	2064.62
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	-108.18	53.38	-35.25	348.29
	(d) Employee benefit expenses	778.50	740.06	664.31	2769.18
	(e) Finance Costs	8.99	12.64	8.82	41.21
	(f) Depreciation and Amortisation Expense	31.62	38.21	36.09	150.02
	(g) other expenses	577.37	266.96	759.03	2920.40
	Total Expenses	2106.00	2206.08	2101.76	9279.93
5	Profit before exceptional items & Tax	310.35	864.55	-291.27	2526.89
6	Exceptional Items	0.00	0.00	0.00	0.00
7	Profit before tax	310.35	864.55	-291.27	2526.89
8	Tax Expense				
	(i) Current Tax	105.00	315.00	0.00	830.00
	(ii) Income Tax for previous years	-32.80	14.24	0.00	14.24
	(ii) Deferred Tax	-31.56	-22.47	-3.33	-38.57
9	Profit after tax for the period	269.71	557.78	-287.94	1721.22
10	Other Comprehensive Income				
	(i) Items that will not be reclassified to profit or loss	0.00	-125.57	0.00	-97.99
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(iii) Items that will be reclassified to profit or loss	7.53	27.60	0.00	27.60
	(iv) Income Tax relating to Items that will be reclassified to profit or loss	-12.11	-0.03	0.00	-0.03
11	Total Comprehensive Income for the period	265.13	459.78	-287.94	1650.80
12	Paid up Equity Share Capital (F.V. Rs.10/- each)	458.94	458.94	464.93	458.94
13	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	5.88	12.15	-6.19	37.50

Notes:

- The Company has adopted Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder from 1st April, 2017 and accordingly, these standalone unaudited financial results (including figures for the previous quarters and year ended 31st March, 2018) have been prepared in accordance with the recognition and measurement principles laid down in Ind AS.
- The above statement of unaudited standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 31st July, 2018.

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

- 3 The EPS calculated above is based on the paidup equity share capital of the Company, for the relevant quarter/year.
- 4 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- 5 The figures of the previous year/period have been regrouped/recast/rearranged to render them comparable with figures of the current period.

Place : Mumbai
Date : 31st July, 2018

By order of the Board
For Jenburkt Pharmaceuticals Ltd.



(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR



 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI -
400034. TEL: 23513758 / 23520330, 9322508373

Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in


Review Report to
The Board of Directors,
Jenburkt Pharmaceuticals Ltd.

We have reviewed the accompanying statement of unaudited financial results of Jenburkt Pharmaceuticals Ltd. for the quarter ended 30th June 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D R Mehta & Associates
Chartered Accountants
(FRN. 106207W)



Signature:
Vikram Mehta
Partner
(M. No.: 047247)

Place: Mumbai
Date: 31st July, 2018

